Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page / d) v2 I# T, S- A; [
" [( u$ |/ A* @3 `, l6 o# Z
, e/ k; l4 C0 |& l) f
Sub-category:3 j$ I- a" F& z/ K! {8 e
Molecular Targets
+ x( [' Z# l2 e, p( y) i2 Q- I1 ?3 F5 i8 u" Q
3 B. `0 C: _8 j9 x, t& g/ p, ?! z0 k
Category:, n, E. z( ^% v- w% Z
Tumor Biology " E3 ` ]' O1 B$ u7 r3 r
4 M: N! a6 O2 L( p! n7 |5 r
* ], K2 g3 Y0 m! }* ?Meeting:. p9 k9 I9 W4 h1 C+ E
2011 ASCO Annual Meeting . o' e1 g; i) x7 z. T9 \
' R" Q* N' g5 [ t) w
9 Z$ T+ T* [, x6 N8 _Session Type and Session Title:9 L$ T% P% W2 A1 M; x
Poster Discussion Session, Tumor Biology
% j2 o) A! c6 H( Z9 ]( G; C
6 i- e: s J$ e. I6 [( [# R X t0 v* f! N5 C4 x
Abstract No: }, i% c6 s* c
10517
+ C/ I$ d' u) Y' S5 d
. a1 r: G+ s9 B0 g0 c8 e* g9 Z! {) a) H C$ r. w
Citation:( N% r2 F1 a# W
J Clin Oncol 29: 2011 (suppl; abstr 10517) 2 \. N, D9 A# e8 z" V, @+ k, y7 k
6 q5 Q- S9 ]1 V# M
4 A% d5 H) C3 l: {9 C% a0 z" @, kAuthor(s):; h5 o( M# e+ A: {, s9 F' G
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
* O) [: n2 }1 L B) ]2 r# L4 } f* p; G1 U% G
/ F% S2 K# @& Q' n/ Y, v7 H& o- j
9 Z7 T F( _! O" x
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
7 p3 Z1 S8 Q4 Z8 O+ n1 [
/ e' ?7 h. o" ]0 k4 C; KAbstract Disclosures
# f! `, O% q; S+ c
5 j2 x) k# e7 VAbstract:5 v; c! y+ S% g- y" W; D$ W
- e; G% q% P, I$ R, ^4 [4 C* h
1 H; c' F2 s* T: ?( W3 A2 PBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
! r% I1 ?1 u. T- Z6 \3 u/ K& N: s$ ]( x( O
& O) r- V E' S2 L |
2 P% o5 f/ l' X) D7 v
显身卡
